Literature DB >> 8834572

Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis.

A D Stephens1, J F Belliveau, P H Sugarbaker.   

Abstract

Intraoperative hyperthermic lavage with cisplatin was studied in 8 patients with peritoneal carcinomatosis and sarcomatosis. A dose of 50 mg/m2 of cisplatin used for 2 hours with an intraperitoneal temperature of 41 degrees to 43 degrees C was used. Pharmacokinetic studies showed that cisplatin left the abdomen and pelvis by simple diffusion with a half life of 48 minutes in the peritoneal fluid. Eighty-six percent of the drug was absorbed into the plasma within 2 hours but only 6.9% was excreted into the urine. The area under the curve ratio for peritoneal fluid to plasma was 6.9. The quantity of cisplatin in tissue from the abdomen or pelvis was extremely variable. It was 1.85-10.28 micrograms cisplatin/g tumor and < 0.57-7.90 micrograms/g normal tissue. Comparison of pharmacologic parameters of hyperthermic to normothermic cisplatin administration showed no significant differences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834572     DOI: 10.1007/978-1-4613-1245-1_3

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  7 in total

1.  A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.

Authors:  Tristan D Yan; Christopher Qian Cao; Stine Munkholm-Larsen
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

Review 2.  Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review.

Authors:  Mikhail Yu Reutovich; Olga V Krasko; Oleg G Sukonko
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 3.  Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.

Authors:  Jessie L-S Au; Ze Lu; M Guillaume Wientjes
Journal:  AAPS J       Date:  2015-06-19       Impact factor: 4.009

Review 4.  Intraperitoneal therapy for peritoneal cancer.

Authors:  Ze Lu; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

5.  Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.

Authors:  P H Cashin; H Ehrsson; I Wallin; P Nygren; H Mahteme
Journal:  Eur J Clin Pharmacol       Date:  2012-09-16       Impact factor: 2.953

Review 6.  Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).

Authors:  Giorgi Nadiradze; Philipp Horvath; Yaroslav Sautkin; Rami Archid; Frank-Jürgen Weinreich; Alfred Königsrainer; Marc A Reymond
Journal:  Cancers (Basel)       Date:  2019-12-20       Impact factor: 6.639

7.  Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC).

Authors:  C Bachmann; I Sautkin; G Nadiradze; R Archid; F J Weinreich; A Königsrainer; M A Reymond
Journal:  Surg Endosc       Date:  2021-06-10       Impact factor: 4.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.